EDITAS MEDICINE INC (EDIT) Fundamental Analysis & Valuation

NASDAQ:EDIT • US28106W1036

Current stock price

3.3599 USD
+0.16 (+5%)
Last:

This EDIT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. EDIT Profitability Analysis

1.1 Basic Checks

  • EDIT had negative earnings in the past year.
  • In the past year EDIT has reported a negative cash flow from operations.
  • In the past 5 years EDIT always reported negative net income.
  • In the past 5 years EDIT always reported negative operating cash flow.
EDIT Yearly Net Income VS EBIT VS OCF VS FCFEDIT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • EDIT's Return On Assets of -85.81% is on the low side compared to the rest of the industry. EDIT is outperformed by 71.32% of its industry peers.
  • EDIT has a Return On Equity of -586.56%. This is in the lower half of the industry: EDIT underperforms 78.49% of its industry peers.
Industry RankSector Rank
ROA -85.81%
ROE -586.56%
ROIC N/A
ROA(3y)-61.97%
ROA(5y)-51.44%
ROE(3y)-269.01%
ROE(5y)-180.58%
ROIC(3y)N/A
ROIC(5y)N/A
EDIT Yearly ROA, ROE, ROICEDIT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for EDIT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EDIT Yearly Profit, Operating, Gross MarginsEDIT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. EDIT Health Analysis

2.1 Basic Checks

  • EDIT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for EDIT has been increased compared to 1 year ago.
  • EDIT has more shares outstanding than it did 5 years ago.
  • EDIT has a worse debt/assets ratio than last year.
EDIT Yearly Shares OutstandingEDIT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
EDIT Yearly Total Debt VS Total AssetsEDIT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • EDIT has an Altman-Z score of -11.83. This is a bad value and indicates that EDIT is not financially healthy and even has some risk of bankruptcy.
  • EDIT's Altman-Z score of -11.83 is on the low side compared to the rest of the industry. EDIT is outperformed by 76.55% of its industry peers.
  • A Debt/Equity ratio of 1.96 is on the high side and indicates that EDIT has dependencies on debt financing.
  • The Debt to Equity ratio of EDIT (1.96) is worse than 79.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.96
Debt/FCF N/A
Altman-Z -11.83
ROIC/WACCN/A
WACC8.94%
EDIT Yearly LT Debt VS Equity VS FCFEDIT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • EDIT has a Current Ratio of 3.54. This indicates that EDIT is financially healthy and has no problem in meeting its short term obligations.
  • EDIT's Current ratio of 3.54 is in line compared to the rest of the industry. EDIT outperforms 42.83% of its industry peers.
  • EDIT has a Quick Ratio of 3.54. This indicates that EDIT is financially healthy and has no problem in meeting its short term obligations.
  • EDIT's Quick ratio of 3.54 is in line compared to the rest of the industry. EDIT outperforms 45.35% of its industry peers.
Industry RankSector Rank
Current Ratio 3.54
Quick Ratio 3.54
EDIT Yearly Current Assets VS Current LiabilitesEDIT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. EDIT Growth Analysis

3.1 Past

  • EDIT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.37%, which is quite impressive.
  • Looking at the last year, EDIT shows a very strong growth in Revenue. The Revenue has grown by 25.40%.
  • The Revenue for EDIT have been decreasing by -14.89% on average. This is quite bad
EPS 1Y (TTM)34.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.09%
Revenue 1Y (TTM)25.4%
Revenue growth 3Y27.15%
Revenue growth 5Y-14.89%
Sales Q2Q%-19.16%

3.2 Future

  • Based on estimates for the next years, EDIT will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.34% on average per year.
  • EDIT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.24% yearly.
EPS Next Y44.29%
EPS Next 2Y21.28%
EPS Next 3Y12.37%
EPS Next 5Y8.34%
Revenue Next Year35.87%
Revenue Next 2Y-7.36%
Revenue Next 3Y-19.83%
Revenue Next 5Y1.24%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EDIT Yearly Revenue VS EstimatesEDIT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M
EDIT Yearly EPS VS EstimatesEDIT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. EDIT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EDIT. In the last year negative earnings were reported.
  • Also next year EDIT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDIT Price Earnings VS Forward Price EarningsEDIT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDIT Per share dataEDIT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as EDIT's earnings are expected to grow with 12.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.28%
EPS Next 3Y12.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EDIT Dividend Analysis

5.1 Amount

  • No dividends for EDIT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EDIT Fundamentals: All Metrics, Ratios and Statistics

EDITAS MEDICINE INC

NASDAQ:EDIT (4/14/2026, 10:23:01 AM)

3.3599

+0.16 (+5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)05-06
Inst Owners52.98%
Inst Owner Change0.08%
Ins Owners0.19%
Ins Owner Change-0.1%
Market Cap328.83M
Revenue(TTM)40.52M
Net Income(TTM)-160.06M
Analysts75
Price Target5.52 (64.29%)
Short Float %12.23%
Short Ratio7.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)42.27%
Min EPS beat(2)7.33%
Max EPS beat(2)77.22%
EPS beat(4)2
Avg EPS beat(4)-8.09%
Min EPS beat(4)-63.79%
Max EPS beat(4)77.22%
EPS beat(8)3
Avg EPS beat(8)-13.54%
EPS beat(12)7
Avg EPS beat(12)-0.47%
EPS beat(16)10
Avg EPS beat(16)0.7%
Revenue beat(2)2
Avg Revenue beat(2)190.42%
Min Revenue beat(2)47.32%
Max Revenue beat(2)333.52%
Revenue beat(4)4
Avg Revenue beat(4)259.45%
Min Revenue beat(4)47.32%
Max Revenue beat(4)546.84%
Revenue beat(8)4
Avg Revenue beat(8)94.69%
Revenue beat(12)7
Avg Revenue beat(12)136.72%
Revenue beat(16)10
Avg Revenue beat(16)109.74%
PT rev (1m)3.75%
PT rev (3m)9.57%
EPS NQ rev (1m)7.3%
EPS NQ rev (3m)14.82%
EPS NY rev (1m)9.08%
EPS NY rev (3m)5.32%
Revenue NQ rev (1m)71.33%
Revenue NQ rev (3m)219.63%
Revenue NY rev (1m)102.01%
Revenue NY rev (3m)113.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.12
P/FCF N/A
P/OCF N/A
P/B 12.05
P/tB 12.05
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0.41
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.81%
ROE -586.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.97%
ROA(5y)-51.44%
ROE(3y)-269.01%
ROE(5y)-180.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 1.96
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.5%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.54
Quick Ratio 3.54
Altman-Z -11.83
F-Score2
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)80.42%
Cap/Depr(5y)92.85%
Cap/Sales(3y)11.62%
Cap/Sales(5y)17.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.09%
EPS Next Y44.29%
EPS Next 2Y21.28%
EPS Next 3Y12.37%
EPS Next 5Y8.34%
Revenue 1Y (TTM)25.4%
Revenue growth 3Y27.15%
Revenue growth 5Y-14.89%
Sales Q2Q%-19.16%
Revenue Next Year35.87%
Revenue Next 2Y-7.36%
Revenue Next 3Y-19.83%
Revenue Next 5Y1.24%
EBIT growth 1Y58.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.77%
EBIT Next 3Y2.41%
EBIT Next 5YN/A
FCF growth 1Y24.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.42%
OCF growth 3YN/A
OCF growth 5YN/A

EDITAS MEDICINE INC / EDIT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EDITAS MEDICINE INC?

ChartMill assigns a fundamental rating of 1 / 10 to EDIT.


What is the valuation status for EDIT stock?

ChartMill assigns a valuation rating of 0 / 10 to EDITAS MEDICINE INC (EDIT). This can be considered as Overvalued.


Can you provide the profitability details for EDITAS MEDICINE INC?

EDITAS MEDICINE INC (EDIT) has a profitability rating of 0 / 10.


How financially healthy is EDITAS MEDICINE INC?

The financial health rating of EDITAS MEDICINE INC (EDIT) is 2 / 10.